News

New Bispecific Antibody Platform - Immunocan Launches Common Light Chain Antibody Discovery Platform: ImmuMab Light® Mouse

New Bispecific Antibody Platform - Immunocan Launches Common Light Chain Antibody Discovery Platform: ImmuMab Light® Mouse

Release Date: 24 June 2022

Boston, June 24, 2024 - Immunocan announces the completion of constructing its fully human common light chain antibody discovery platform, ImmuMab Light® mouse. This new platform will further enhance Immunocan's antibody discovery capabilities and make the development of fully human IgG-like bispecific antibodies easier.

Read More
Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline

Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline

Release Date: 21 December 2023

ImmuMab Heavy® mice are able to produce fully human antibodies, consisting solely of heavy chains, without the presence of light chains. These mice possess over 120 human immunoglobulin heavy-chain V genes at the mouse immunoglobulin gene loci, thanks to the parental strain ImmuMab® mice.

Read More
Immunocan pioneers Mb gene replacement technology to create a new fully human antibody mouse platform

Immunocan pioneers Mb gene replacement technology to create a new fully human antibody mouse platform

Release Date: 03 December 2022

Along with the continuous development of antibody-based drug technology, monoclonal antibody drugs and innovative therapeutics based on monoclonal antibodies (bispecific antibody,

Read More
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse

Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse

Release Date: 01 June 2024

Boston, June 01, 2024 - Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by alpaca IGH-VDJ genes in-situ.

Read More
ImmuMab® mice generated Consistent and Stable Immune Responses as Wild-type Mice-Immunocan accelerating development of fully human antibodies

ImmuMab® mice generated Consistent and Stable Immune Responses as Wild-type Mice-Immunocan accelerating development of fully human antibodies

Release Date: 12 April 2023

In December 2022, Shanghai Immunocan Biotech Co., Ltd. launched ImmuMab® mouse, a fully human antibody discovery platform based on patented gene editing technology, and initiated mouse evaluation and application projects. Thus far, the four projects from different antigens have demonstrated stable immune responses as wild type mice, laying a solid foundation for further development of therapeutic antibodies.

Read More
Immunocan raised 50 million RMB in pre-A financing, led by Kingray Capital

Immunocan raised 50 million RMB in pre-A financing, led by Kingray Capital

Release Date: 16 August 2021

On August 16th, according to the report from the investment community, Shanghai Immunocan Biotech Co. (hereinafter referred to as “Immunocan”), a fully human antibody drug development company, has completed a Pre-A round of financing of RMB 50 million recently.

Read More